The Wall Street Journal: With Shkreli out, KaloBios touts reasonably priced drugs

KaloBios Pharmaceuticals, the drugmaker that was briefly taken over by former pharmaceuticals executive Martin Shkreli last year, said Monday it will charge cost plus a “reasonable and transparent profit margin” for any drugs it produces.